MarketsWindlas Biotech Limited WINDLAS
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 907.35 | 760.45 | 626.21 |
| Accumulated Depreciation Total | -148.16 | -118.61 | -92.06 |
| Cash Equivalents | 0.48 | 0.21 | 0.15 |
| Other Liabilities Total | 3.33 | 2.98 | 2.5 |
| Accrued Expenses | 32.66 | 34.47 | 30.38 |
| Long Term Debt | 0.1 | 0 | 0 |
| Common Stock Total | 10.55 | 10.48 | 10.4 |
| Other Equity Total | -0.05 | -0.05 | -0.04 |
| Other Current Assets Total | 0.03 | 0.18 | 24.92 |
| Prepaid Expenses | 1.39 | 1.05 | 0.98 |
| Total Assets | 907.35 | 760.45 | 626.21 |
| Current Portof LT Debt/Capital Leases | 33.09 | 30.35 | 1.62 |
| Additional Paid-In Capital | 202.91 | 198.94 | 194.6 |
| Cash | 0.51 | 0.42 | 5.27 |
| Total Equity | 580.84 | 505.77 | 449.94 |
| Long Term Investments | 1.75 | 0.97 | 1.98 |
| Retained Earnings(Accumulated Deficit) | 347.76 | 291.15 | 240.09 |
| Total Common Shares Outstanding | 2.11 | 2.1 | 2.08 |
| Property/Plant/Equipment Total-Gross | 414.17 | 340.53 | 272.35 |
| Tangible Book Valueper Share Common Eq | 271.92 | 238.08 | 214.18 |
| Total Liabilities | 326.51 | 254.68 | 176.27 |
| Total Debt | 35.34 | 32.6 | 3.64 |
| Short Term Investments | 278.28 | 238.85 | 199.07 |
| Cashand Short Term Investments | 279.28 | 239.48 | 204.49 |
| Total Receivables Net | 281.52 | 201.15 | 137.71 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 227.83 | 167.45 | 136.94 |
| Property/Plant/Equipment Total-Net | 266.01 | 221.93 | 180.29 |
| Total Current Liabilities | 320.93 | 249.44 | 171.75 |
| Total Inventory | 64.63 | 83.27 | 63.18 |
| ESOP Debt Guarantee | 19.66 | 5.25 | 4.89 |
| Accounts Payable | 238.49 | 167.24 | 131.51 |
| Other Currentliabilities Total | 16.68 | 17.39 | 8.24 |
| Total Long Term Debt | 2.25 | 2.25 | 2.02 |
| Intangibles Net | 6.91 | 6.78 | 4.47 |
| Other Long Term Assets Total | 4.98 | 3.7 | 2.96 |
| Note Receivable-Long Term | 0.85 | 1.94 | 5.22 |
| Total Current Assets | 626.85 | 525.13 | 431.29 |
| Capital Lease Obligations | 2.15 | 2.25 | 2.02 |
Valuation and ratios
Valuation
PEG Ratio1.71
Price to Sale Ratio0.20
Growth
Debt 5Yr CAGR %1.79
Margins
Operating Margin 12m8.18
Operating Margin 5y Avg8.96
Net Profit Margin 12m7.35
Net Profit Margin 5y8.14
Yield
Dividend Yield %0.72
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk32.17
Recommendations
Target High1,095
Target Low699.35
Target Mean0
Target Median0
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Sun Pharmaceutical Industries | INR 1,937.6 | 4.65 L | 38.4 | — |
| — | Divi's Laboratories | INR 7,368.55 | 1.96 L | 73.32 | — |
| — | Torrent Pharmaceuticals | INR 4,972.75 | 1.68 L | 72.73 | — |
| — | Cipla | INR 1,409.1 | 1.14 L | 27.57 | — |
| — | Zydus Lifesciences | INR 1,121.3 | 1.12 L | 21.19 | — |
Ownership
- Promoter
- 63.31%
- FII
- 2.04%
- MF
- 5.76%
- Other
- 28.89%
Events
- annual General MeetingAGM
- dividendRs.6.3000 per share(126%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingBuy Back of Shares.
- board MeetingsBuy Back of Shares
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.5.8000 per share(116%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingRs.5.5000 per share(110%)Dividend & A.G.M.
- dividendRs.5.5000 per share(110%)Dividend
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results & Dividend
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Dividend Stocks: Shree Cement and Orient Bell are among the key stocks to trade ex-dividend today on 21 July 2025. Among other stocks to trade ex-date are Acceleratebs India, Anupam Rasayan India, OCCL, Thangamayil Jewellery, and Windlas Biotech. Check dividend payout and other details.
Sumeet Bagadia recommended buying these seven breakout shares to buy today - Aavas Financiers, Windlas Biotech, HEG, A B Infrabuild, and Elecon Engineering Company.
Breakout stocks to buy: Sumeet Bagadia recommends five shares to buy today — Windsor Machines, TTL, Suven Pharma, Paradeep Phosphates, and Windlas Biotech
Business information
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- WINDLAS
- BSE Code
- 543329
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Windlas Biotech?
Windlas Biotech has the symbol WINDLAS and ISIN - INE0H5O01029.
What is the current price of Windlas Biotech?
Windlas Biotech is currently trading at INR 863.15.
What are the year high and year low of Windlas Biotech?
Windlas Biotech has a year high of INR 1,095.00 and a year low of INR 699.35.
What is the market capitalization of Windlas Biotech?
Windlas Biotech has a market capitalization of INR 1,845.91 crore.
What is the P/E ratio of Windlas Biotech?
Windlas Biotech has a P/E ratio of 23.36.
What is the dividend yield of Windlas Biotech?
Windlas Biotech has a dividend yield of 0.72%.
How is the financial performance of Windlas Biotech based on revenue, net income, and EPS?
Windlas Biotech has revenue of INR 9,040.89 crore, net income of INR 664.56 crore, and EPS of INR 31.18.
What is the book value of Windlas Biotech?
Windlas Biotech has a book value of INR 271.92.
What is the debt-to-equity ratio of Windlas Biotech?
Windlas Biotech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Windlas Biotech?
Windlas Biotech has a price-to-book ratio of 3.17 and a price-to-sales ratio of 0.20.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
